NCT07095114RecruitingNot Applicable
A Phase I/II Study of Disappearing Markers for Daily Radiation Treatment Delivery
Barbara Ann Karmanos Cancer Institute2 sites in 1 country30 target enrollmentStarted: August 18, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 30
- Locations
- 2
- Primary Endpoint
- Safety of Magic Ink
Study Overview
Brief Summary
The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are:
- Is the Magic Ink as safe as standard tattoo ink
- Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery
- •Participants must be 18 years of age or older
- •Participant must be able to understand a written informed consent document and be willing to sign it
- •Participant must be assigned female at birth
- •Participant must have a Karnofsky performance score of greater than or equal to 70%
- •Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following:
- •Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy
- •Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation
- •Agree to practice true abstinence from sexual intercourse
- •Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship)
- •If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception.
- •For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6
Exclusion Criteria
- •Participants who have received prior radiation treatment to the affected breast.
- •Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink
- •Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study
- •Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued
- •Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.
Arms & Interventions
Magic Ink tattoo
Experimental
Magic Ink tattoo ink which is only visible when exposed to ultraviolet light will be used to mark radiation guidance
Intervention: Magic Ink (Other)
Outcomes
Primary Outcomes
Safety of Magic Ink
Time Frame: 3 months after completion of Radiation Therapy
Number of participants with treatment related adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0)
Secondary Outcomes
- Efficacy of Magic Ink(3 months after the completion of Radiation Therapy)
- Body Image Score(3 months after the completion of Radiation Therapy)
Investigators
Michael Dominello
Principal Investigator
Barbara Ann Karmanos Cancer Institute
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control GelAcne VulgarisNCT03653403Bausch Health Americas, Inc.61
Completed
Unknown
Development for certificated medical markers using safe pigments for precise marking on surgical field in the human body.Diseases requiring tooth extraction, jaw deformity, jawbone cyst, jawbone tumor, oral mucosal tumor,JPRN-jRCTs032230078Maruoka Yutaka5
Unknown
Not Applicable
Study for the Validation of a New Biomarker to Determine Predisposition to Infections in Patients With Acute Myocardial Infarction.Infections in Acute Myocardial Infarction PatientsNCT05412732Instituto de Investigación Hospital Universitario La Paz300
Recruiting
Phase 1
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT05766748Cantex Pharmaceuticals30
Completed
Phase 1
Azeliragon and Chemoradiotherapy in Newly Diagnosed GlioblastomaGlioblastomaNCT05635734Cantex Pharmaceuticals33